When does Wegovy start working for weight loss — and what should you expect?

The first few weeks: appetite shifts before the scales do

A common thing people tell us (and one worth gently setting aside) is that Wegovy should produce dramatic weight loss within days. It does not, and that is not a sign it is failing. What semaglutide does first is work on the appetite-regulating centres in the brain and slow how quickly food leaves the stomach. Those changes begin with your very first dose.

In practice, the earliest signal most people notice is that they feel full on less food, or that the urge to snack between meals quietly fades. If you are curious about when Wegovy starts working and what the first signs look like, most people notice something in the first week, while others take two to three weeks to feel any difference, particularly at the 0.25 mg starting dose, which is low by design. The stepped schedule (moving through 0.5 mg, 1.0 mg, 1.7 mg and eventually 2.4 mg) exists to give your digestive system time to adapt and to reduce the nausea and stomach upset that can otherwise occur. Weight loss at this stage may be modest; one to two kilograms across the first month is typical for many people, though some see more and others less.

The NHS patient information for semaglutide explains the dose escalation and what to expect at each stage. Our Wegovy treatment overview covers the licence and eligibility criteria in more detail.

Months two to six: where the evidence says weight loss gathers pace

Once you reach the 1.7 mg and 2.4 mg doses (typically from around month four or five) the appetite-suppressing effect is at its strongest, and weight loss usually accelerates. This is the phase that the large clinical trials measured most closely.

The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks. Participants on 2.4 mg semaglutide lost an average of around 15% of body weight, compared with around 2.4% on placebo. Understanding when weight loss typically starts on Wegovy helps explain why that reduction did not arrive in a single month; the loss curve continued to descend through month 16 and beyond, meaning patience is genuinely rewarded. People who lost a modest amount in the first two months often continued to see steady progress once they were established on the maintenance dose.

Individual results vary considerably. Starting BMI, how consistently you follow a reduced-calorie diet alongside treatment, activity levels and whether side effects led to any dose pauses all influence the pace. A prescriber reviewing your progress can help interpret whether your trajectory looks right for you, or whether something needs adjusting. If you are weighing up how Wegovy compares on a cost basis, the weight-loss treatment overview gives useful context.

When you might not see the progress you expected

If weight loss has been less than 5% of starting body weight after six months at the maintenance dose, clinical guidelines suggest reviewing whether to continue. NICE guidance on semaglutide (TA875) includes exactly this checkpoint. That does not mean six months without any change (most people see some reduction earlier) but it is the formal threshold at which a prescriber would look carefully at what is happening.

Several factors can slow progress that are worth knowing about. Nausea at a new dose sometimes leads people to eat less but also to avoid the higher-protein foods that support muscle retention; leaning on soft, easy-to-digest options during that adjustment period can reduce the quality of weight lost even as the quantity looks reasonable. Alcohol slows gastric emptying further and can amplify side effects. And the medicine does not override a significant calorie surplus, appetite reduction makes eating less easier, but it is not an override switch.

If something feels off (whether that is unexpected symptoms, a plateau you cannot explain, or simply uncertainty) our aftercare team is available seven days a week. Hearing when Wegovy started working for other people can offer useful perspective, though questions about your individual dosing timeline always go back to your prescriber, not to general guidance.

What the Wegovy 7.2 mg dose means for the longer timeline

In April 2026 the MHRA approved a higher 7.2 mg maintenance dose of Wegovy, initially available as three 2.4 mg pens per week, then as a dedicated single-dose 7.2 mg pen for adults with a BMI of 30 or above. Trials reported average weight loss of around 20.7% over 72 weeks at this dose, narrowing the gap with tirzepatide results. For eligible people who have already reached and tolerated 2.4 mg, this represents a further step rather than a separate starting point; the titration journey from 0.25 mg still applies.

What this adds to the timeline picture is that semaglutide's ceiling may be higher than the original 2.4 mg data suggested. For people who reach the maintenance dose and plateau before hitting their clinical target, there is now a licensed pathway to discuss with a prescriber. Specific dose availability is confirmed during your consultation. You can read more about the semaglutide treatment pathway or explore how to access Wegovy through a regulated UK pharmacy.

Wegovy is a prescription-only medicine. Starting your consultation with nume is straightforward, a GPhC-registered prescriber reads your answers the same day and makes a clinical decision on suitability. If that is something you are considering, you can start your free consultation here.